Latest news with #AlkemLaboratories
News18
4 days ago
- Business
- News18
Alkem Q1 profit rises 22 pc to Rs 664 cr
Agency: PTI Last Updated: New Delhi, Aug 12 (PTI) Alkem Laboratories on Tuesday said its net profit increased 22 per cent year-on-year to Rs 664 crore during the June quarter. Total revenue from operations stood at Rs 3,371 crore with year-on-year growth of 11 per cent. 'Q1 FY26 marked a strong start to the year, with healthy growth across both our domestic and international markets," Alkem CEO Vikas Gupta said in a statement. The company's performance was driven by strong topline growth and an improved gross margin, which resulted in a better EBITDA profile, he added. 'We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high-potential non-US markets and capturing new opportunities that align with our long-term growth ambitions," Gupta added. PTI MSS TRB First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
&w=3840&q=100)
Business Standard
4 days ago
- Business
- Business Standard
Alkem Labs Q1 profit rises 22% to ₹664 cr on India, overseas sales growth
Alkem Laboratories on Tuesday reported a 22 per cent year-on-year (Y-o-Y) rise in its consolidated net profit for the June quarter (Q1FY26) to ₹664.3 crore, up from ₹545.2 crore in the same period last year. Revenue from operations increased 11.2 per cent Y-o-Y to ₹3,371 crore in Q1FY26 from ₹3,031 crore in Q1FY25. The company attributed this growth to strong sales in both India and international markets. Commenting on the performance, Vikas Gupta, Chief Executive Officer of Alkem, said Q1FY26 marked a strong start to the year, with healthy growth across both domestic and overseas markets. India sales grew 12 per cent Y-o-Y to ₹2,265 crore in the June quarter, while international sales rose 8.9 per cent to ₹1,054 crore, contributing 31.7 per cent to overall revenue. In the international business, the United States market recorded sales of ₹698 crore, up 8.8 per cent from ₹641.6 crore a year earlier, contributing 21 per cent to total sales. Sales from other international markets — including Latin America, Australia, and Europe — rose 9.1 per cent to ₹355.6 crore, contributing 10.7 per cent to revenue. Gupta said the company is strategically accelerating its focus on the non-US business segment by strengthening its presence in high-potential markets and capturing new opportunities aligned with Alkem's long-term growth ambitions. Alkem also announced it will incorporate a Saudi Arabia-based subsidiary, holding a 51 per cent stake. 'The subsidiary is proposed to be incorporated as a limited liability company and will be involved in the manufacture, import, marketing, and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia,' the company said in a filing to the exchanges. On Tuesday, Alkem Laboratories' share price rose 6.7 per cent to close at ₹5,167 on the Bombay Stock Exchange (BSE).
Business Standard
4 days ago
- Business
- Business Standard
Alkem Laboratories partners with Abdulaziz Alsheikh to incorporate subsidiary in KSA
Alkem Laboratories has, pursuant to a shareholders' agreement dated 12 August, 2025, agreed to incorporate a subsidiary company in the Kingdom of Saudi Arabia. Pursuant to incorporation of such subsidiary, the Company will hold 51% of the total share capital. The balance stake of 49% will be held by Abdulaziz Alsheikh (Saudi Partner). The subsidiary is proposed to be incorporated as a limited liability company and will be involved in the manufacture, import, marketing and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia.
Business Standard
5 days ago
- Business
- Business Standard
Alkem Laboratories consolidated net profit rises 21.85% in the June 2025 quarter
Sales rise 11.19% to Rs 3371.14 crore Net profit of Alkem Laboratories rose 21.85% to Rs 664.26 crore in the quarter ended June 2025 as against Rs 545.16 crore during the previous quarter ended June 2024. Sales rose 11.19% to Rs 3371.14 crore in the quarter ended June 2025 as against Rs 3031.82 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 3371.143031.82 11 OPM % 21.9220.08 - PBDT 845.76699.84 21 PBT 758.08619.36 22 NP 664.26545.16 22
Business Upturn
5 days ago
- Business
- Business Upturn
Alkem Laboratories Q1 Results: Revenue jumps 11.2% YoY to Rs 3,371 crore, net profit up Rs 21.45% YoY
By Aman Shukla Published on August 12, 2025, 13:40 IST Alkem Laboratories has delivered a strong set of numbers for the first quarter of FY26, with growth across revenue, profit, and operational performance. The company reported a consolidated net profit of ₹668 crore, marking a solid 21.45% year-on-year jump from ₹550 crore in the same quarter last year. Revenue also saw healthy growth, rising 11.2% to ₹3,371 crore compared to ₹3,031.8 crore a year ago. The pharmaceutical major's EBITDA stood at ₹739 crore, up 21.35% from ₹609 crore, with margins improving to 21.9% from 20% in the previous year. The domestic business remained the key growth driver, clocking sales of ₹2,265 crore, a 12% increase from the previous year, contributing 68.3% to total sales. According to IQVIA (SSA) data, the company outperformed the Indian Pharmaceutical Market (IPM) in seven therapies, including Gastrointestinal, Vitamins/Minerals/Nutrients, Pain Management, Anti-Diabetics, Neuro/CNS, Respiratory, and Dermatology, with growth ranging from 1.1x to 2.3x the market rate. On the international front, sales stood at ₹1,053.9 crore, registering an 8.9% year-on-year rise. The US business contributed ₹698.2 crore, up 8.8% from last year and accounting for 21% of total sales. Non-US international markets generated ₹355.6 crore, up 9.1%, contributing 10.7% to total revenue. In the US market, Alkem filed its first Biologics License Application (BLA), received five ANDA approvals (including two tentative), and launched three new products during the quarter. As of June 30, 2025, the company had filed 185 ANDAs, two NDAs, and one BLA with the USFDA, receiving approvals for 160 ANDAs (including 15 tentative) and both NDAs. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
